Google Ads for Weight Loss Centers

Most paid search advice assumes you can retarget people who visited your site and did not convert. In this category you cannot. Google classifies weight loss alongside reproductive health, mental health, and addiction as a sensitive area, and remarketing based on that interest is not permitted. Personalized advertising for health and wellness products, services, and procedures is likewise restricted, which removes a second set of tools most accounts lean on. Add the platform requirement that ads not imply knowledge of a user's personal characteristics, the eighteen and over targeting requirement, and the certification process attached to restricted drug terms including GLP-1 medications, and you are running paid search with roughly half the standard toolkit unavailable. That is not a reason to avoid the channel. It is a reason to build the account differently from the outset, because most disapprovals and suspensions in this vertical come from advertisers who set up a normal account and discovered the rules afterwards.

1What You Actually Cannot Do

Start here, because every strategic decision downstream depends on it. Published summaries of Google's health advertising policies and reporting from practitioners in this category consistently describe the following constraints.

• No remarketing on weight loss interest. Google prohibits remarketing for sensitive health categories, and weight loss is named among them alongside reproductive health, mental health, and addiction.
• No personalized advertising. Health and wellness products, services, and procedures are excluded from personalized ad tools, which affects audience targeting broadly rather than remarketing alone.
• No implying knowledge of the user. Copy phrased as your condition, your symptoms, or anything suggesting you know something personal about the reader is not permitted.
• Eighteen and over targeting. Weight loss advertising must be age restricted.
• No unrealistic claims. Google's misrepresentation policy names misleading or unrealistic weight loss claims explicitly as a violation.
• Specific product prohibitions. hCG in connection with weight loss is prohibited, as is implying a product is as effective as a prescription drug or controlled substance.

Microsoft's rules run parallel and in some respects tighter, with published summaries noting that ads related to sensitive health conditions targeting consumers are not permitted and that similar language restrictions apply.

We do not build accounts that attempt to route around any of this. Practitioners in restricted categories occasionally discuss cloaking or similar evasion tactics, and the outcome of those approaches is account suspension rather than cheaper leads. In a business where your ad account is a primary acquisition channel, losing it is a materially worse problem than a higher cost per lead.

2Building Without Remarketing

This is the structural problem that defines paid search in this vertical. Choosing a weight loss programme is a considered decision that people revisit over weeks or months, which is precisely the situation remarketing exists to serve, and it is unavailable to you.

The consequence is that first-visit conversion matters far more here than in comparable service categories, and that owned channels have to carry the follow-up work that retargeting carries elsewhere.

1. Capture contact details earlier. A low-commitment step such as a consultation booking or an information request is worth more here than in categories where you could simply retarget the visitor later.
2. Move follow-up to email and phone. Once someone has given you their details and appropriate consent, nurture happens through channels you own rather than through ad platforms.
3. Invest in the first session. Page speed, clarity, and a straightforward next step matter disproportionately when there is no second chance through the ad platform.
4. Lean on organic and local. A person who is going to think about this for six weeks will search again, and being present organically is how you are there the second time.
5. Use brand search as the safety net. Someone who remembers your name and searches it later is the closest available substitute for a retargeted impression.

Any agency proposing a weight loss remarketing programme is either unaware of the policy or planning to violate it. Both are reasons to ask more questions.

3Claims Language and the Misrepresentation Policy

Claims are where platform policy and federal enforcement overlap, and where the consequences extend well beyond a disapproved ad.

The Federal Trade Commission brought an action in July 2025 against telehealth provider NextMed over what it characterised as misleading prices, fake reviews, and deceptive weight loss claims in the marketing of GLP-1 programmes, with a final order approved in December 2025. Industry compliance analysis of this sector lists marketing claims, specifically testimonials, before and after photographs, and weight loss numbers, among the highest-frequency enforcement risks alongside clinical documentation failures.

That is worth sitting with, because those three things are the standard creative toolkit in this category. A results number in a headline, a transformation photograph, and a patient quote are what most weight loss advertising is built from, and they are the items regulators are looking at.

What we do instead is advertise the service rather than the outcome. Physician supervision, what an initial consultation involves, programme structure, how care is delivered, credentials, and cost transparency are all defensible, differentiating, and unlikely to attract regulatory attention. Your counsel should review claims language before it runs, and we build on the assumption that they will.

4Medication Terms and Certification

If your clinic prescribes GLP-1 medications, the advertising rules tighten again. Google maintains a list of restricted drug terms which published analysis indicates includes GLP-1 and prescription weight loss products, and advertising in that space requires certification. Where an agency runs the campaigns, that agency needs formal authorisation as part of the process.

The regulatory backdrop moved substantially between 2024 and 2026 and it affects what can be advertised at all. The FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage in February 2025, which narrowed the basis for mass compounding of those products. In February and March 2026 the agency issued warning letters to around thirty telehealth companies over claims made about compounded GLP-1 products, following more than a hundred letters in 2025, with the Commissioner describing it as a new era of enforcement. Separately, manufacturers have pursued large numbers of lawsuits and National Advertising Division challenges against clinics, compounders, and telehealth companies marketing compounded versions.

The practical marketing consequence is direct. Advertising inexpensive compounded semaglutide to the general public is not a campaign we will build, because the FDA has publicly identified that pattern as a target. If your business model depends on it, the conversation you need is with healthcare counsel about the model, not with an agency about ad copy.

Where you prescribe branded medication under proper clinical process, that is advertisable within the certification framework, and the campaign should emphasise the clinical process rather than the drug.

5Campaign Structure by Service Model

Weight loss centres are not one business. The compliance surface, the buyer, and the economics differ substantially depending on what you actually deliver, and campaigns should be separated accordingly.

Keeping these apart matters for a reason beyond reporting clarity. A disapproval or policy issue in one campaign is easier to contain when it is not sitting in the same campaign as everything else you run, and separation makes it far quicker to identify which asset triggered a review.

6Keyword Strategy in a Restricted Category

Keyword work here divides into terms that are straightforward, terms that require care, and terms that invite trouble.

Straightforward terms describe the service and the setting. Weight loss clinic, medical weight loss, weight loss doctor, weight management programme, and the same terms with your city attached. These carry clear intent and none of the claim risk.

Terms requiring care include medication names and category terms, which sit inside the restricted drug framework and should only run where certification is in place and the destination page is appropriate. Programme cost terms are worth capturing but the landing experience has to present pricing honestly, since the FTC action in this sector specifically cited misleading price presentation.

Terms to avoid include anything built on rapid results, guaranteed outcomes, or specific figures, and anything framed around body dissatisfaction. These attract disapproval, they attract regulatory attention, and they select for prospects with expectations your clinical team will then have to manage down.

Negatives matter more than usual. Block recipe, DIY, supplement shopping, job seeking, and academic research traffic, and block terms associated with unsupervised medication purchase, since that traffic is both worthless and reputationally awkward to be visible against.

7Landing Pages That Survive Review

In restricted categories the destination page is reviewed as part of the ad, so a compliant ad pointing at a non-compliant page fails. The page carries most of the risk.

• State who provides care and their credentials. Physician supervision is both a compliance asset and your strongest differentiator against unsupervised operators.
• Present pricing completely. Programme cost, what is included, whether medication is separate, and subscription terms including cancellation. Incomplete pricing was a named element of federal enforcement in this sector.
• Describe the process, not the promise. What happens at the first appointment, how the plan is built, how often the patient is seen, and how progress is reviewed.
• Keep the imagery neutral. Clinical settings and staff rather than transformation photography.
• Avoid pressure mechanics. Countdown timers and scarcity framing on a medical service read badly to reviewers and to patients.

A separate technical point worth raising with your compliance officer: if your site uses tracking pixels on pages where patients enter information or access records, that arrangement needs review under health privacy rules before it runs, not after.

8Handling Disapprovals and Account Risk

Expect disapprovals in this category. They are not automatically a sign of bad work, and the way they are handled determines whether they stay minor.

The process that works is unexciting. Read the specific policy cited rather than guessing. Fix the asset rather than resubmitting unchanged. Appeal only where you genuinely believe the classification is wrong, and document what changed. Repeatedly resubmitting borderline material is how a disapproval becomes an account level problem.

Keep the account itself resilient. Do not run every campaign under a single point of failure, keep billing and business verification current, and maintain a record of what was approved and when so a reviewer's question can be answered quickly.

The wider point is that account suspension in a restricted vertical is difficult to reverse and costly while it lasts. That risk is why we decline evasion tactics even when a client asks for them, and it is worth agreeing that position before the first campaign launches rather than during an appeal.

9Measuring Without Personalized Data

Restrictions on personalized advertising also constrain measurement, so reporting in this vertical needs to work from your own systems rather than from platform audience data.

Measure to consultations booked, consultations attended, and programme enrolments rather than to form fills. The gap between a form fill and an attended consultation is wide in this category, and optimising toward the former reliably produces more of the wrong enquiries.

Import enrolments back into the platform where your systems and your privacy obligations permit, and take advice on that specifically, since health data flowing into advertising platforms is exactly the arrangement that regulators have been examining. Where that is not appropriate, run the analysis outside the platform and use it to inform manual decisions instead.

Then report on programme value rather than first payment, since most weight loss centres sell programmes with a duration and a retention curve, and a single transaction figure understates what an enrolment is worth.

For general platform mechanics rather than this vertical's restrictions, our Google Ads guide covers campaign types, bidding, and structure.